ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Clinical Epidemiology

September 20, 2022
Plasma metabolomic profiles were examined to determine differences in social determinants of health between Black and white women. This observational study paves the groundwork for further investigation of social disparity in atheromatous disease.
July 1, 2022
This is an interesting, well-written account of pooled results of two medium-size RCTs . It would be interesting to see a third arm of optimum medical therapy in follow-up studies ...
June 23, 2022
This scientific statement is a granular contribution to a major cardiovascular issue, illuminating nuances of the "generally recognized as safe" (GRAS) FDA designation. One would expect the relevant Thoracic Associations in North America and Europe to contribute to this debate.
May 26, 2022
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
April 5, 2022
A brief but comprehensive editorial on nuances of the links between atrial fibrillation and heart failure, apropos a trial we have commented recently on, by the Johns Hopkins team that develops the calmodulin-dependent protein kinase II inhibitor molecules   
March 4, 2022
A paper that addresses a gap in knowledge and will guide future research: of particular interest, the penultimate paragraph on The Role of Interventions.
November 1, 2021
An extremely useful and free-access update on a major vascular entity. The 'Areas of Uncertainty'  is a particularly useful chapter, discussing the available technology and its current supra-renal limitations and the emerging solutions.
October 22, 2021
A brief focused commentary on a recent medium size Japanese series of succesful surgery for Acute Aortic Syndrome. The limitations of the series presented in well- written Uchida manuscript( and already to the last AATS Meeting) are being explored, and the commentators' allusion to the need for randomised trial is evident.
October 21, 2021
A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes.
June 15, 2021
Fascinating confirmation of null hypotheses including bleeding complications and survival in a Pennsylvanian cohort study, despite the easily predictable previous PCI, hock, and IABP prevalence in the emergency group. The statistical model is elaborate and complex. Perhaps a randomized trial could now be justified!

Pages